U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT07477444) titled 'Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer (HER-OIC)' on March 12.
Brief Summary: The HER-OIC clinical trial is a Phase 1b/2a study investigating a new combination of treatments for patients with HER2-positive gastroesophageal cancer. Standard treatment for localized gastroesophageal cancer usually involves chemotherapy before and after surgery. This study aims to see if adding targeted therapy (zanidatamab) and immunotherapy (tislelizumab) to standard chemotherapy is safe and effectively eliminates the tumor. The goal is to improve the pathological complete response (pCR) rate, which is th...